Contacts

Bulgarian Organized Research Activities (BORA)
1618 Sofia, Bulgaria
12 Nov vek Str.
"Ovcha kupel"
Office 2
mobile: +359 899 813 206
mobile: +359 887 744 672
e-mail: office@bora-cro.com
http://bora-cro.com/


Lambda-Plus is a leading European provider of user-friendly and cost-effective Electronic Data Capture (EDC) and Electronic Data Management (EDM) solutions customized to support local and international ph. II-IV clinical trials, registries and PMS projects.

Activities

Major qualifications
Monitoring and management of clinical trials; medical affairs (more than 10 years of experience)

  • Phase II - IV clinical trials;
  • Bioavailability/Bioequivalence trials;
  • Project management;
  • Logistics;
  • Medical writing;
  • Medical advisor;
  • Pharmacovigilance;
  • Legal expert on clinical trials in Bulgaria;
  • Regulatory support on Bulgarian drug legislation regarding clinical trials.
  • Regulatory policies and legislation rilated to clinical trials at the Bulgarian Drug Agency

Drug regulatory affairs - (more than 20 years of experience)

  • Regulatory policies directed to marketing authorization procedures at the Bulgarian Drug Agency (DP and MRP and national procedures) and also
  • Consultants services at EMEA level where the Bulgarian language (SmPC and PIL) is needed;
  • Advises on local requirements for national applications as well as MRP, decentralized and centralized (NCES, Variations, renewals);
  • Provide intelligence on legislative changes (ongoing and future) to local requirements;
  • Prepare good quality translations where needed. In particular to translate packaging, artworks and SPCs and prepare local artworks.
  • For centralized products to meet the EMEA translation timings.
  • To submit and co-ordinate maintenance related to approved products as necessary (variations, renewals, PSURs).

Related to clinical trials affairs

Intellectual properties for pharmaceuticals in Bulgaria

Outcome research

Training activities:

In the field of clinical trials:

  • Initial training on the role and responsibilities of the CRA, Study Site Staff and Sponsor plus the Local Regulations and International ICH Guidelines and Good Clinical Practice (GCP).
  • "Hands on experience" in actual monitoring situations such as Investigator Selection, Contacts with Regulatory Authority and Ethics Committees, CRF Review, SDV, Drug Accountability and Adverse Event assessment.
  • Additional training on different topics, key for the monitoring excellence:
    • The EU clinical trial Directive;
    • Adverse events - Understanding and Reporting Requirements;
    • Detecting Fraud and Misconduct in Clinical trials;
    • Improving Investigator Site Performance;
    • Developing of training courses according to client's needs;

In the field of Regulatory Affairs:

Training on:

  • Pharmaceutical legislation in the EU (Directives and Regulations)
  • Marketing authorization procedures;
  • Pharmacovigilance;
  • Pricing and reimbursement;